JP2011502994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011502994A5 JP2011502994A5 JP2010532265A JP2010532265A JP2011502994A5 JP 2011502994 A5 JP2011502994 A5 JP 2011502994A5 JP 2010532265 A JP2010532265 A JP 2010532265A JP 2010532265 A JP2010532265 A JP 2010532265A JP 2011502994 A5 JP2011502994 A5 JP 2011502994A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- group
- halogen
- optionally
- aliphatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 132
- 229910052736 halogen Inorganic materials 0.000 claims description 68
- 150000002367 halogens Chemical class 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 61
- 125000001931 aliphatic group Chemical group 0.000 claims description 57
- 229910052799 carbon Inorganic materials 0.000 claims description 57
- 229920006395 saturated elastomer Polymers 0.000 claims description 42
- 125000005843 halogen group Chemical group 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 229910052760 oxygen Inorganic materials 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- 239000003054 catalyst Substances 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 24
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 20
- 230000001404 mediated effect Effects 0.000 claims description 20
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 16
- 125000002950 monocyclic group Chemical group 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 229910052751 metal Inorganic materials 0.000 claims description 12
- 239000002184 metal Substances 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- 102000001892 Protein Kinase C-theta Human genes 0.000 claims description 10
- 108010015499 Protein Kinase C-theta Proteins 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 8
- 125000002837 carbocyclic group Chemical group 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 8
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 claims description 8
- 102000001253 Protein Kinase Human genes 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 108060006633 protein kinase Proteins 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- JZZJAWSMSXCSIB-UHFFFAOYSA-N 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound COB1OC(C)(C)C(C)(C)O1 JZZJAWSMSXCSIB-UHFFFAOYSA-N 0.000 claims description 4
- 101150003085 Pdcl gene Proteins 0.000 claims description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 4
- 102000003923 Protein Kinase C Human genes 0.000 claims description 4
- 108090000315 Protein Kinase C Proteins 0.000 claims description 4
- 238000006069 Suzuki reaction reaction Methods 0.000 claims description 4
- 208000000389 T-cell leukemia Diseases 0.000 claims description 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 125000003725 azepanyl group Chemical group 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 claims description 4
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 claims description 4
- 125000005959 diazepanyl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 238000007363 ring formation reaction Methods 0.000 claims description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000018937 joint inflammation Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 claims 1
- -1 or -T1-Q1 Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 0 *C(*)(*)c1cc(*)cc(-c2c(*)cnc3c2c(*)n[n]3)c1 Chemical compound *C(*)(*)c1cc(*)cc(-c2c(*)cnc3c2c(*)n[n]3)c1 0.000 description 17
- ISYOFZCEMBXHOL-UHFFFAOYSA-M [Li].CC(C)[Mg]Cl Chemical compound [Li].CC(C)[Mg]Cl ISYOFZCEMBXHOL-UHFFFAOYSA-M 0.000 description 2
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98487507P | 2007-11-02 | 2007-11-02 | |
| US60/984,875 | 2007-11-02 | ||
| US4457508P | 2008-04-14 | 2008-04-14 | |
| US61/044,575 | 2008-04-14 | ||
| US10080808P | 2008-09-29 | 2008-09-29 | |
| US61/100,808 | 2008-09-29 | ||
| PCT/US2008/081933 WO2009073300A1 (en) | 2007-11-02 | 2008-10-31 | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011502994A JP2011502994A (ja) | 2011-01-27 |
| JP2011502994A5 true JP2011502994A5 (OSRAM) | 2012-12-13 |
| JP5444239B2 JP5444239B2 (ja) | 2014-03-19 |
Family
ID=40220120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532265A Expired - Fee Related JP5444239B2 (ja) | 2007-11-02 | 2008-10-31 | タンパク質キナーゼＣ−θとしての［１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン−４−イル］−フェニレンまたは−ピリジン−２−イル誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8173635B2 (OSRAM) |
| EP (1) | EP2215089B1 (OSRAM) |
| JP (1) | JP5444239B2 (OSRAM) |
| KR (1) | KR20100093552A (OSRAM) |
| CN (1) | CN101903384A (OSRAM) |
| AR (1) | AR069174A1 (OSRAM) |
| AU (1) | AU2008331733A1 (OSRAM) |
| CA (1) | CA2704266A1 (OSRAM) |
| CL (1) | CL2008003280A1 (OSRAM) |
| ES (1) | ES2389992T3 (OSRAM) |
| IL (1) | IL205458A0 (OSRAM) |
| MX (1) | MX2010004819A (OSRAM) |
| NZ (1) | NZ585063A (OSRAM) |
| TW (1) | TW200924762A (OSRAM) |
| WO (1) | WO2009073300A1 (OSRAM) |
| ZA (1) | ZA201003050B (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3456189B2 (ja) | 2000-03-31 | 2003-10-14 | 日本電気株式会社 | 移動通信システム |
| NZ601687A (en) | 2006-01-17 | 2014-03-28 | Vertex Pharma | Azaindoles useful as inhibitors of janus kinases |
| CA2673472A1 (en) * | 2006-12-21 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | 5-cyan0-4- (pyrrolo) [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| WO2009073300A1 (en) | 2007-11-02 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
| EP2262498A2 (en) * | 2008-03-10 | 2010-12-22 | Vertex Pharmceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
| US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| AU2009279611A1 (en) * | 2008-08-06 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Aminopyridine kinase inhibitors |
| CN105924386A (zh) * | 2009-03-25 | 2016-09-07 | Abbvie 公司 | 抗病毒化合物和其用途 |
| JP5627675B2 (ja) * | 2009-05-06 | 2014-11-19 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ピラゾロピリジン |
| PH12015501678B1 (en) | 2009-06-17 | 2022-07-06 | Vertex Pharma | Inhibitors of influenza viruses replication |
| CN102858769A (zh) * | 2010-01-27 | 2013-01-02 | 沃泰克斯药物股份有限公司 | 吡唑并吡啶激酶抑制剂 |
| WO2011094290A1 (en) | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrimidine kinase inhibitors |
| MX2012008642A (es) * | 2010-01-27 | 2012-11-23 | Vertex Pharma | Inhibidores de cinasas de pirazolopiridinas. |
| CA2787079A1 (en) | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrazine kinase inhibitors |
| JP2013525481A (ja) * | 2010-05-05 | 2013-06-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ＰＫＣ−θインヒビターとして有用な４置換ピラゾロピリミジン |
| AU2011343642A1 (en) | 2010-12-16 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| RU2013132683A (ru) | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
| KR20130128436A (ko) | 2010-12-16 | 2013-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2013184985A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| PL3686181T3 (pl) | 2013-01-30 | 2024-11-04 | Ecolab Usa Inc. | Zmiatacze siarkowodoru |
| AU2014348752C1 (en) | 2013-11-13 | 2019-11-21 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| JP6615755B2 (ja) | 2013-11-13 | 2019-12-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | インフルエンザウイルスの複製の阻害剤 |
| MX2016007898A (es) | 2013-12-20 | 2016-10-07 | Signal Pharm Llc | Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos. |
| WO2016004305A2 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| JP6640840B2 (ja) * | 2014-09-22 | 2020-02-05 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 線維症を処置するための方法及び医薬組成物 |
| CN107438601B (zh) | 2015-04-22 | 2020-11-13 | 艺康美国股份有限公司 | 开发用于去除硫化氢的高温稳定清除剂 |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| US10407626B2 (en) | 2015-09-08 | 2019-09-10 | Ecolab Usa Inc. | Hydrocarbon soluble/dispersible hemiformals as hydrogen sulfide scavengers |
| CA2997416C (en) | 2015-09-08 | 2023-06-27 | Ecolab Usa Inc. | Hydrogen sulfide scavengers |
| EP3491106B1 (en) | 2016-07-29 | 2020-07-15 | Ecolab Usa Inc. | Antifouling and hydrogen sulfide scavenging compositions |
| NZ750781A (en) * | 2016-09-09 | 2025-06-27 | Novartis Ag | Compounds and compositions as inhibitors of endosomal toll-like receptors |
| WO2019014415A1 (en) | 2017-07-13 | 2019-01-17 | Ecolab USA, Inc. | METHOD FOR REMOVING A COMPOUND CONTAINING SULFUR BY ADDITION OF A COMPOSITION |
| EP3914676A1 (en) | 2019-01-23 | 2021-12-01 | ChampionX USA Inc. | Complete removal of solids during hydrogen sulfide scavenging operations using a scavenger and a michael acceptor |
| MX2021012285A (es) * | 2019-04-09 | 2021-12-15 | Nurix Therapeutics Inc | Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico. |
| CN111529533B (zh) * | 2020-06-05 | 2021-06-11 | 南华大学附属第一医院 | 溴结构域蛋白4抑制剂jq1或其衍生物在制备治疗脓毒症肠屏障损伤药物中的应用 |
| JP2024518447A (ja) * | 2021-05-06 | 2024-05-01 | エクセンシア・エイアイ・リミテッド | ＰＫＣ－θモジュレーター |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2080531A (en) * | 1936-01-08 | 1937-05-18 | United Shoe Machinery Corp | Manufacture of shoes |
| US3314941A (en) * | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
| GB1159487A (en) | 1968-04-04 | 1969-07-23 | Standard Telephones Cables Ltd | Capacitors |
| US4988705A (en) * | 1985-06-13 | 1991-01-29 | Schering Corporation | Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives |
| JP2890448B2 (ja) | 1988-04-26 | 1999-05-17 | 日産化学工業株式会社 | ピラゾロピリジン系メバロノラクトン類 |
| US5100768A (en) * | 1989-05-09 | 1992-03-31 | Kabushiki Kaisha Toshiba | Photosensitive composition |
| JPH03206450A (ja) * | 1990-01-09 | 1991-09-09 | Fuji Photo Film Co Ltd | 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料及びその処理方法 |
| JPH03271289A (ja) | 1990-03-16 | 1991-12-03 | Nissan Chem Ind Ltd | ピラゾロピリジン誘導体の製造法及びジヒドロピラゾロピリジン誘導体 |
| US5338740A (en) * | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
| US5646330A (en) * | 1995-02-17 | 1997-07-08 | Ciba-Geigy Corporation | Production of enantiomerically enriched ortho-substituted α,α-diaromatic methanols |
| US6194581B1 (en) * | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| US6452008B2 (en) * | 1998-02-25 | 2002-09-17 | Sumitomo Pharmaceuticals Company, Limited | Pyridone derivatives and process for preparing the same |
| GB9908410D0 (en) * | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| AR029289A1 (es) * | 2000-07-05 | 2003-06-18 | Ishihara Sangyo Kaisha | Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo |
| JP2002020386A (ja) | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
| DE10035908A1 (de) * | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
| WO2002020500A2 (en) * | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| GB0128287D0 (en) | 2001-11-26 | 2002-01-16 | Smithkline Beecham Plc | Novel method and compounds |
| JP2005516927A (ja) * | 2001-12-13 | 2005-06-09 | アボット・ラボラトリーズ | 癌治療用のキナーゼ阻害剤としての３−（フェニル−アルコキシ）−５−（フェニル）−ピリジン誘導体および関連化合物 |
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| DE10222550A1 (de) * | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
| EP2508204B1 (en) * | 2002-06-26 | 2014-09-24 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases caused by vascular contraction or dilation |
| CA2495216A1 (en) | 2002-08-12 | 2004-02-19 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| EP1590334B1 (en) * | 2003-01-30 | 2009-08-19 | Boehringer Ingelheim Pharmaceuticals Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
| JP2006519846A (ja) | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター：使用および合成の方法 |
| US20050203067A1 (en) * | 2003-05-12 | 2005-09-15 | Hresko Michelle C. | Pesticidal compositions and methods |
| CN1867334A (zh) * | 2003-07-22 | 2006-11-22 | 詹森药业有限公司 | 作为c－fms激酶抑制剂的喹啉酮衍生物 |
| WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
| JP4805166B2 (ja) * | 2003-12-22 | 2011-11-02 | バジリア ファルマスーチカ アーゲー | アロイルフランおよびアロイルチオフェン |
| UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| US7812166B2 (en) * | 2004-10-29 | 2010-10-12 | Abbott Laboratories | Kinase inhibitors |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| EP1812450A2 (en) | 2004-11-10 | 2007-08-01 | Eli Lilly And Company | Tgf-beta inhibitors |
| DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| WO2006101456A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors |
| CN101218241B (zh) * | 2005-05-16 | 2011-02-16 | Irm责任有限公司 | 用作蛋白激酶抑制剂的吡咯并吡啶衍生物 |
| NZ563444A (en) | 2005-05-17 | 2011-04-29 | Plexxikon Inc | Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors |
| DE102005035417A1 (de) | 2005-07-28 | 2007-02-01 | Robert Bosch Gmbh | Entfernungsmessgerät und Verfahren zum Befestigen einer elektrooptischen Einheit an einer Leiterträgereinheit |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| DE102005048897A1 (de) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| JP2009521504A (ja) | 2005-12-22 | 2009-06-04 | スミスクライン・ビーチャム・コーポレイション | Ａｋｔ活性阻害剤 |
| CA2635899A1 (en) * | 2006-01-19 | 2007-07-26 | Osi Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| US8796293B2 (en) | 2006-04-25 | 2014-08-05 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| TW200815438A (en) * | 2006-06-13 | 2008-04-01 | Bayer Schering Pharma Ag | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| CN105693730A (zh) | 2006-10-19 | 2016-06-22 | 西格诺药品有限公司 | 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途 |
| JP2008132121A (ja) * | 2006-11-28 | 2008-06-12 | Sanshin Kinzoku Kogyo Kk | 移動ラック装置 |
| JP5528812B2 (ja) | 2006-12-20 | 2014-06-25 | アムジエン・インコーポレーテツド | 複素環式化合物ならびに炎症、血管形成および癌の治療におけるこれらの使用 |
| WO2008132121A1 (en) * | 2007-04-26 | 2008-11-06 | Glaxo Group Limited | Lh-indazole-3-amine compounds as ikk1 inhibitors |
| WO2009073300A1 (en) | 2007-11-02 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
-
2008
- 2008-10-31 WO PCT/US2008/081933 patent/WO2009073300A1/en not_active Ceased
- 2008-10-31 ES ES08857976T patent/ES2389992T3/es active Active
- 2008-10-31 KR KR1020107012153A patent/KR20100093552A/ko not_active Withdrawn
- 2008-10-31 TW TW097142239A patent/TW200924762A/zh unknown
- 2008-10-31 JP JP2010532265A patent/JP5444239B2/ja not_active Expired - Fee Related
- 2008-10-31 EP EP08857976A patent/EP2215089B1/en active Active
- 2008-10-31 MX MX2010004819A patent/MX2010004819A/es active IP Right Grant
- 2008-10-31 AU AU2008331733A patent/AU2008331733A1/en not_active Abandoned
- 2008-10-31 US US12/262,459 patent/US8173635B2/en not_active Expired - Fee Related
- 2008-10-31 CA CA2704266A patent/CA2704266A1/en not_active Abandoned
- 2008-10-31 CN CN2008801218567A patent/CN101903384A/zh active Pending
- 2008-10-31 NZ NZ585063A patent/NZ585063A/en not_active IP Right Cessation
- 2008-11-03 AR ARP080104815A patent/AR069174A1/es unknown
- 2008-11-03 CL CL2008003280A patent/CL2008003280A1/es unknown
-
2010
- 2010-04-29 IL IL205458A patent/IL205458A0/en unknown
- 2010-04-30 ZA ZA2010/03050A patent/ZA201003050B/en unknown
-
2011
- 2011-10-18 US US13/275,551 patent/US8367697B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011502994A5 (OSRAM) | ||
| JP4971300B2 (ja) | イミダゾピリダジン化合物 | |
| JP6839104B2 (ja) | ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン | |
| JP2020117514A (ja) | Ｒｏｒガンマ調節物質としての置換型テトラヒドロキノリン化合物 | |
| JP2021073299A (ja) | ピリミジニルチロシンキナーゼ阻害剤 | |
| JP2015502387A5 (OSRAM) | ||
| CA2813437A1 (en) | Furo[3,2-d]pyrimidine compounds | |
| JP4880097B1 (ja) | Ｈｉｖインテグラーゼ阻害剤 | |
| KR20150042830A (ko) | 인간 면역결핍 바이러스 복제의 억제제 | |
| SG181147A1 (en) | Novel tricyclic compounds | |
| EP2305682A1 (en) | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | |
| Sun et al. | Pyridine-phosphinimine ligand-accelerated Cu (i)-catalyzed azide–alkyne cycloaddition for preparation of 1-(pyridin-2-yl)-1, 2, 3-triazole derivatives | |
| JP7045528B2 (ja) | Ｈｉｖに感染した細胞に対する選択的細胞毒性薬としてのピリミドン誘導体 | |
| Goryaeva et al. | The reactions of 2-ethoxymethylidene-3-oxo esters and their analogues with 5-aminotetrazole as a way to novel azaheterocycles | |
| CN105189510A (zh) | 人免疫缺陷病毒复制的抑制剂 | |
| JP2024519993A (ja) | キノリンアミン系化合物、その調製方法及びその医薬的応用 | |
| Yu et al. | Facile, eco-friendly, catalyst-free synthesis of polyfunctionalized 2-aminopyrroles | |
| EP3227298A1 (en) | Process for the preparation of baricitinib and an intermediate thereof | |
| Wójtowicz-Rajchel et al. | Synthesis of 5-fluorovinyl derivatives of pyrimidines via Suzuki–Miyaura coupling and their 1, 3-dipolar cycloaddition reactions with nitrones | |
| KR102295416B1 (ko) | 1-(피페라진-1-일)-2-([1,2,4]트리아졸-1-일)-에타논 유도체 | |
| Beaudoin et al. | Efficient, scalable syntheses of important intermediates in tribenzotriquinacene chemistry | |
| JP2021505555A (ja) | ベンゼン縮合複素環化合物およびその使用 | |
| Frebault et al. | A concise access to 3-substituted 2-pyrones. | |
| JP2022512812A (ja) | Ｂ型肝炎ウイルス疾患の処置及び予防のための新規三環式化合物 | |
| JP2013530239A5 (OSRAM) |